Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 19/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 17/20 | 0.61 |
| ▸ | PDE2A | O00408 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991078 | 0.76 | PTGDR (1.00) | PTGDRTBXA2RPDE2A | |
| SCHEMBL13317687 | 0.69 | PTGDR (0.75) | PTGDRTBXA2RPDE2A | |
| SCHEMBL12923781 | 0.68 | TBXA2R (0.80) | PTGDRTBXA2R | |
| SCHEMBL14401191 | 0.65 | TBXA2R (0.73) | PTGDRTBXA2R | |
| SCHEMBL14449868 | 0.64 | PTGDR (1.00) | PTGDRTBXA2RPDE2A | |
| SCHEMBL991127 | 0.64 | TBXA2R (1.00) | PTGDRTBXA2RPDE2A | |
| SCHEMBL14401271 | 0.64 | PTGDR (0.85) | PTGDRTBXA2RPDE2A | |
| SCHEMBL990454 | 0.64 | TBXA2R (1.00) | PTGDRTBXA2RPDE2A | |
| SCHEMBL13176193 | 0.59 | PTGDR (0.81) | PTGDRTBXA2R | |
| SCHEMBL24460563 | 0.54 | ALDH1A1 (0.55) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612106-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | FFAR1, HCAR1, GPR119 | PTGDR 527/4885TBXA2R 68/4885PDE2A 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.